Biofil Chemicals & Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26
Biofil Chemicals & Pharmaceuticals Ltd · Outcome · 15 Nov 2026, 12:16 am
Biofil Chemicals & Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 167 (-87.7% YoY | -86.5% QoQ) ■ EBITDA: 10.3 (-10.4% YoY | -27.1% QoQ) ■ EBITDA Margin (%): 6.1 (+530 bps YoY | +500 bps QoQ) ■ PAT: 11.5 (+37.9% YoY | +5.7% QoQ) ■ EPS (INR): 0.07 (+40.0% YoY | +0.0% QoQ) Biofil Chemicals & Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) Segmental Performance Pharma Unit ■ Revenue: 167 (-86.3% YoY | -46.8% QoQ) ■ EBIT: 1.3 (-82.5% YoY | Loss to Profit QoQ) ■ EBIT Margin (%): 0.8 (+16 bps YoY | Loss to Profit QoQ) Chemicals Division ■ Revenue: 0.0 (-100.0% YoY | -100.0% QoQ) ■ EBIT: 10.2 (+2123.9% YoY | -33.7% QoQ) ■ EBIT Margin (%): 0.0 (-33 bps YoY | -167 bps QoQ)
Original exchange filing (PDF)
More announcements from Biofil Chemicals & Pharmaceuticals Ltd
- Biofil Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 15 Nov 2026
- To review, consider and approve the Standalone Unaudited Financial Results for the quarter and half year ended on 30th September 2026 along with limited review report · 15 Nov 2026
- BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 14-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business. · 14 Nov 2026
- Biofil Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve Unaudited .... · 14 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 and other business matters · 14 Nov 2026
- Continuous disclosure of Material event or information for which disclosure as required under sub-clause 7 of Part A Para A Schedule III : 1 .Continuation of directorship of Mr. Ashok .... · 24 Sept 2026
- Scruitinizer report with voting results · 24 Sept 2026
- Summary of Proceedings of 41st Annual General Meeting of the company held on Wednesday, 23rd September 2026 pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI .... · 23 Sept 2026
